Oxcia is a Swedish drug company that is dedicated to revolutionizing treatments for cancer and inflammation. Their vision is to become a globally profitable company by conducting leading-edge research and providing life-changing therapies for patients in need. Oxcia focuses on targeting oxidative stress and DNA Damage Response, with the goal of saving and improving lives worldwide.

Oxcia's strategy revolves around building an innovative pharmaceutical company in Sweden through cutting-edge science and operational excellence. They prioritize indications with high unmet needs, aiming to obtain orphan drug status/fast track and/or conditional approval to expedite market access. Oxcia develops products for the global market and holds a broad IP portfolio across Europe, the US, Asia, and other regions.

With a team driven by a passion for groundbreaking science and patient well-being, Oxcia collaborates with scientific experts, clinicians, and other industry stakeholders to find innovative solutions. They are actively seeking collaborations and license agreements with pharmaceutical and biotech companies, as well as academic research groups. Highlighted by a diversified portfolio and being one of the pioneers in the DNA Damage Response field, Oxcia has two clinical stage drug candidates targeting cancer and inflammation.

They aim for fast track and/or conditional approval for their lead compound, which is orally administered and offers convenience and improved quality of life for patients. Oxcia has demonstrated good tolerability and excellent safety in pre-clinical and phase 1 trials. Backed by a management team with over 200 years of combined experience in the pharmaceutical industry, Oxcia has a strong IP portfolio and boasts extensive pre-clinical research conducted in collaboration with universities and big pharma companies worldwide.

For those interested in contacting Oxcia, they can be reached at their headquarters in Stockholm, Sweden